Prosecution Insights
Browse Companies Examiners Firms Draft Your Response
Home / Novartis AG / Complete list
Last updated: October 24, 2026

Novartis AG: all pending office actions

← Back to Novartis AG

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19575321 THERAPEUTIC ANTI-BAFF-R ANTIBODIES DUTT, ADITI 1675 DP Non-Final OA — Pending Mar 23, 2026
19240908 METHOD OF TREATING PROSTATE CANCER PERREIRA, MELISSA JEAN 1618 §103DP Non-Final OA 32d overdue Pending Jun 17, 2025
19234864 STABLE, CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION MEJIAS, SAMANTHA LEE 1618 §103Other Final Rejection 76d Pending Jun 11, 2025
19176436 PHARMACEUTICAL COMPOSITIONS OF RIBOCICLIB YOUNG, MICAH PAUL 1618 §102§103 Non-Final OA 41d Pending Apr 11, 2025
19065656 SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES ABBAS, SYED JARAR 1674 §112 Final Rejection — Pending Feb 27, 2025
18982128 TABLET FORMULATION OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YLMETHYL)IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE NESTOR, DONNA MICHELLE 1629 §112Other Non-Final OA — Pending Dec 16, 2024
18977210 Ribociclib Tablet FUBARA, BLESSING M 1613 §103DP Final Rejection 88d overdue Pending Dec 11, 2024
18871590 CRYSTALLINE FORMS OF AN AKRIC3 DEPENDENT KARS INHIBITOR MOORE, SUSANNA 1624 §102§112DP Non-Final OA — Pending Dec 04, 2024
18960021 NEW CRYSTALLINE FORMS OF SALT OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE -6-CARBOXYLIC ACID DIMETHYLAMIDE WHITE, DAWANNA SHAR-DAY 1627 §103DP Non-Final OA — Pending Nov 26, 2024
18939314 PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF KUCHARCZK, JED A 1623 §112DP Non-Final OA — Pending Nov 06, 2024
18909652 NLRP3 INFLAMMASOME INHIBITORS COUGHLIN, MATTHEW P 1626 §102§103Other Non-Final OA — Pending Oct 08, 2024
18851253 COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF BARSKY, JARED 1628 §112 Non-Final OA — Pending Sep 26, 2024
18687609 CRYSTALLINE FORMS OF BIARYL YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS CLARK, AMY LYNN 1628 §102§103§112Other Non-Final OA — Pending Sep 24, 2024
18845258 ACETONITRILE RECOVERY PROCESS MILLER, JONATHAN 1626 §103§112 Non-Final OA — Pending Sep 09, 2024
18843599 USE OF IPTACOPAN FOR THE TREATMENT OF LUPUS NEPHRITIS SHI, GENBIN 1628 §103§112 Non-Final OA — Pending Sep 03, 2024
18802089 IMMUNOSUPPRESSANT FORMULATIONS ROSENTHAL, ANDREW S 1613 §103 Final Rejection — Pending Aug 13, 2024
18797888 Octreotide Depot Formulation with Constantly High Exposure Levels WESTERBERG, NISSA M 1618 §112DP Non-Final OA — Pending Aug 08, 2024
18797142 NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER WARD, PAUL V 1622 DP Non-Final OA — Pending Aug 07, 2024
18730975 RIBOCICLIB PHARMACEUTICAL COMPOSITIONS LADD, CAROLYN LOUISE — §103 Non-Final OA — Pending Jul 22, 2024
18729949 SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF FETTEROLF, BRANDON J 1626 §102 Non-Final OA — Pending Jul 18, 2024
18739657 COMBINATION HUI, SAN MING R 1627 §103 Non-Final OA — Pending Jun 11, 2024
18672871 ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF BENAVIDES, JENNIFER ANN 1675 §102§103§112DP Non-Final OA — Pending May 23, 2024
18670859 NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER PATEL, SAGAR S 1626 §112Other Non-Final OA — Pending May 22, 2024
18655058 FACTOR XI ANTIBODIES AND METHODS OF USE SZPERKA, MICHAEL EDWARD 1641 §112DP Non-Final OA — Pending May 03, 2024
18703559 METHODS FOR IMPROVING ADENO-ASSOCIATED VIRUS (AAV) DELIVERY YU, DAVID TUYANG 1635 §102§103§112 Non-Final OA — Pending Apr 22, 2024
18628570 USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER SAMALA, JAGADISHWAR RAO 1618 §102§112 Final Rejection — Pending Apr 05, 2024
18628097 METHODS OF TREATING NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS USING INTERLEUKIN-17 (IL-17) ANTAGONISTS CARTER, SANDRA DILLAHUNT 1674 §103§112DP Non-Final OA — Pending Apr 05, 2024
18696753 SURFACTANT STABILIZERS KENYON, JOHN S 1625 §102§112 Non-Final OA — Pending Mar 28, 2024
18687599 Dosing Regimen for a TEAD inhibitor VALENROD, YEVGENY 1628 §112Other Non-Final OA — Pending Feb 28, 2024
18588259 Ribociclib Tablet FUBARA, BLESSING M 1613 §102§103DP Final Rejection — Pending Feb 27, 2024
18685551 LOU064 FOR TREATING MULTIPLE SCLEROSIS CHAO, ALLEN 1622 §103 Final Rejection — Pending Feb 22, 2024
18444288 PROTEIN SOLUTION FORMULATION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY KIM, YUNSOO 1641 §102§103DP Non-Final OA — Pending Feb 16, 2024
18683858 OFATUMUMAB FOR TREATING PEDIATRIC MS AEDER, SEAN E 1642 §103DP Non-Final OA — Pending Feb 15, 2024
18440783 LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER SAMALA, JAGADISHWAR RAO 1618 DP Non-Final OA 91d overdue Pending Feb 13, 2024
18423776 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF COLEMAN, BRENDA LIBBY 1624 §112DP Non-Final OA — Pending Jan 26, 2024
18424004 COMPOSITIONS AND METHODS FOR INCREASING MUSCLE GROWTH HAMA, JOANNE 1647 DP Non-Final OA — Pending Jan 26, 2024
18291083 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS LEE, WILLIAM Y 1623 §103§112 Non-Final OA — Pending Jan 22, 2024
18391485 METHODS OF TREATING CHRONIC SPONTANEOUS URTICARIA USING LIGELIZUMAB SZPERKA, MICHAEL EDWARD 1641 §102§103 Non-Final OA — Pending Dec 20, 2023
18569346 PHARMACEUTICAL FORMULATION CONTAINING AN ANTI-IgE ANTIBODY LIU, SUE XU 1646 §102§103§112 Non-Final OA — Pending Dec 12, 2023
18562108 METHODS FOR THE TREATMENT OF OSTEOARTHRITIS METCALF, MATTHEW CURRAN 1647 §101§102§103DP Non-Final OA — Pending Nov 17, 2023
18561444 FORMULATIONS OF 3-((3-(4-(2-(ISOBUTYLSULFONYL)PHENOXY)-3-(TRIFLUOROMETHYL)PHENYL)-1,2,4-OXADIAZOL-5-YL)METHYL)-5,5-DIMETHYL-1-(2-MORPHOLINOETHYL)IMIDAZOLIDINE-2,4-DIONE RAO, SAVITHA M 1691 §102§103§112Other Non-Final OA 8d overdue Pending Nov 16, 2023
18559859 DOSING REGIMENS ENGLISH, CONNOR KENNEDY 1625 §103 Non-Final OA — Pending Nov 09, 2023
18558766 IPTACOPAN FOR THE TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME HERNANDEZ, JACKSON J 1627 §103DP Final Rejection 17d overdue Pending Nov 03, 2023
18558729 TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS USING ANTI-BAFFR ANTIBODIES MCCOLLUM, ANDREA K 1674 §102§103§112DP Non-Final OA — Pending Nov 02, 2023
18288345 VIRAL VECTOR PRODUCTION SYSTEM STAVROU, CONSTANTINA E 1632 §102§103§112 Non-Final OA — Pending Oct 25, 2023
18554778 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1-(((S)-OXETAN-2-YL)METHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY BORALSKY, LUKE ALAN 1624 §102§112Other Final Rejection 53d overdue Pending Oct 10, 2023
18552760 DIAGNOSTIC METHODS OF PROSTATE CANCER ROGERS, JAMES WILLIAM 1618 §103§112 Non-Final OA — Pending Sep 27, 2023
18281732 FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE HEASLEY, MEGHAN CHRISTINE 1626 §103§112Other Non-Final OA — Pending Sep 12, 2023
18550004 HIGH THROUGHOUT SCREENING IN DROPLETS BUNKER, AMY M 1684 §103 Final Rejection — Pending Sep 11, 2023
18454457 ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF BENAVIDES, JENNIFER ANN 1675 §102§103§112DP Non-Final OA — Pending Aug 23, 2023
17997137 CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER SKOKO III, JOHN JOSEPH 1643 §102§103§112Other Non-Final OA 14d Pending Aug 08, 2023
18363237 MOLECULES THAT BIND TO AND STABILIZE TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 (TREM2) DUTT, ADITI 1675 §103§112 Non-Final OA — Pending Aug 01, 2023
18261523 PHARMACEUTICAL COMPOSITION GOTFREDSON, GAREN 1619 §102§103§112Other Final Rejection 27d Pending Jul 14, 2023
18352345 NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES NIEBAUER, RONALD T 1658 §103§112DP Non-Final OA — Pending Jul 14, 2023
18253903 EXPRESSION TECHNOLOGY FOR ANTIBODY CONSTRUCTS MONTANARI, DAVID A 1632 §103§112 Non-Final OA 55d Pending May 22, 2023
18251913 ANTIBODY Fc VARIANTS HOWARD, ZACHARY C 1674 §112Other Final Rejection 37d overdue Pending May 05, 2023
18034326 USE OF AN IL-18 ANTAGONIST FOR TREATING AND/OR PREVENTION OF ATOPIC DERMATITIS OR A RELATED CONDITION BUNNER, BRIDGET E 1647 §103 Non-Final OA — Pending Apr 27, 2023
18187242 USE OF CANAKINUMAB HOWARD, ZACHARY C 1674 §102§112 Non-Final OA 34d Pending Mar 21, 2023
18184860 BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF SKELDING, ZACHARY S 1644 §102§112Other Non-Final OA — Pending Mar 16, 2023
18178886 SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES HUYNH, PHUONG N 1641 §112Other Non-Final OA 15d overdue Pending Mar 06, 2023
18019469 TREATMENT OF B CELL MALIGNANCIES KAUFMAN, CLAIRE M 1674 §103 Non-Final OA 6d Pending Feb 02, 2023
18019467 TREATMENT OF CLL KAUFMAN, CLAIRE M 1674 §103 Final Rejection 6d Pending Feb 02, 2023
18009568 ZBTB32 INHIBITORS AND USES THEREOF RAHMAN, MASUDUR 1633 §102§103 Final Rejection — Pending Dec 09, 2022
18061221 METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS WU, JULIE ZHEN QIN 1643 §101§112Other Non-Final OA 49d Pending Dec 02, 2022
18061227 METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS EDGINGTONGIORDANO, FRANCESCA 1643 Other Non-Final OA — Pending Dec 02, 2022
17997299 METHODS FOR RADIOLABELING PSMA BINDING LIGANDS AND THEIR KITS DONOHUE, SEAN R 1618 §103 Final Rejection 71d overdue Pending Oct 27, 2022
17973773 VERTEBRATE CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A POLYPEPTIDE OF INTEREST NGUYEN, QUANG 1631 §112DP Final Rejection — Pending Oct 26, 2022
17995820 OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG WANG, CHANG YU 1675 §103§112DP Final Rejection 35d overdue Pending Oct 07, 2022
17813843 COMPOSITIONS AND METHODS FOR DECREASING TAU EXPRESSION MARVICH, MARIA 1634 §112DP Non-Final OA — Pending Jul 20, 2022
17771353 CRIZANLIZUMAB CONTAINING ANTIBODY FORMULATIONS BERHANE, SELAM 1675 §103§112DP Final Rejection — Pending Apr 22, 2022
17642285 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE BELL, SARA ELIZABETH 1625 §102§112 Non-Final OA — Pending Mar 11, 2022
17753635 Management of conditions other than multiple sclerosis in ofatumumab-treated patients WANG, CHANG YU 1675 §103 Final Rejection 60d overdue Pending Mar 09, 2022
17753632 TREATMENT OF RMS BY SWITCHING THERAPY AEDER, SEAN E 1600 §103DP Non-Final OA — Pending Mar 09, 2022
17640293 THERAPEUTIC FUSION PROTEINS DEBERRY, REGINA M 1647 §112 Non-Final OA 19d overdue Pending Mar 03, 2022
17620987 DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN NICKOL, GARY B 1643 §102§103 Final Rejection 15d overdue Pending Dec 20, 2021
17616900 Use of an Anti-P-selectin Antibody HADDAD, MAHER M 1641 §103 Final Rejection — Pending Dec 06, 2021
17613889 METHOD FOR NAVIGATING MEDICAL DATA CHOI, PETER H 3681 §103 Non-Final OA 2d overdue Pending Nov 23, 2021
17612280 ANTIBODY DRUG CONJUGATES HAVING LINKERS COMPRISING HYDROPHILIC GROUPS VAN DRUFF, SYDNEY 1643 §103 Final Rejection — Pending Nov 18, 2021
17432868 COMBINATION THERAPIES OF EGFRVIII CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS CHASE, CAROL ANN 1646 §102§103§112 Final Rejection — Pending Aug 20, 2021
17309403 AAV VIRAL VECTORS AND USES THEREOF RIGA, MICHAEL ANGELO 1634 §103 Final Rejection 66d overdue AI Ready May 25, 2021
17057561 Automatic Drug Delivery Device FREHE, WILLIAM R 3783 §103 Non-Final OA — Pending Nov 20, 2020
16980679 METHODS FOR TREATING OCULAR DISEASES FONTAINHAS, AURORA M 1675 §103Other Non-Final OA — Pending Sep 14, 2020
18566259 SUBSTITUTED INDOLE COMPOUNDS AND METHODS OF USE THEREOF CHONG, YONG SOO 1623 §102Other Final Rejection — Pending Dec 01, 2023
18015856 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY CHICKS, ASHLI ARIANA 1626 §102§103§112 Non-Final OA 133d overdue Pending Jan 12, 2023
17766149 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SCHMIDT, IZABELA MARIA 1621 §102§112Other Non-Final OA 264d overdue Pending Apr 01, 2022
17376829 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SHTERENGARTS, SAMANTHA L 1623 §102 Non-Final OA 117d overdue Pending Jul 15, 2021

Data sourced from USPTO Patent File Wrapper (daily) and Office Action Archive (weekly). Analysis generated by IP Author.

Data: USPTO Patent File Wrapper (daily) • Office Action Archive (weekly) • 89M+ prosecution events

© 2026 IP Author — Browse Office Actions • Examiners • Companies • Firms

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month